Trial Profile

A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MEDI 6012 (Primary)
Indications Myocardial infarction
Focus Therapeutic Use
Acronyms REAL-TIMI 63B
Sponsors AstraZeneca; MedImmune

Most Recent Events

30 Aug 2022 Primary endpoint has not been met (Infarct size; infarct size as a percentage of left ventricular mass by cardiac MRI at 10 to 12 weeks) , according to Results published in the Circulation
30 Aug 2022 Results published in the Circulation
17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com